

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT PROPOSED ADOPTION OF SHARE OPTION SCHEME

Reference is made to the prospectus of China Resources Pharmaceutical Group Limited (the “**Company**”) dated 17 October 2016 (the “**Prospectus**”). As disclosed in the Prospectus, the Company may implement a share option scheme or incentive scheme after the listing of the Company on the Main Board of The Stock Exchange of Hong Kong Limited, subject to the approval by the board of directors (the “**Board**”) and the shareholders of the Company (the “**Shareholders**”) as well as approval of the State-owned Assets Supervision and Administration Commission of the State Council of the People’s Republic of China (the “**SASAC**”).

The Board is pleased to announce that, on 24 August 2017, the Board has resolved to propose the adoption of a share option incentive scheme (the “**Scheme**”) for the approval by the Shareholders.

The purpose of the Scheme is to effectively retain and attract exceptional talents through a further optimized remuneration structure, align the interests of the employees and shareholders and effectively motivate both the management team and key employees, thereby fostering the long-term development of the Company and maximising the interests of shareholders.

The Scheme will constitute a share option scheme under Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The Board will convene a general meeting for the purposes of, among other things, seeking the approval from the Shareholders for the adoption of the Scheme and authorising the Board to grant the share options pursuant to the Scheme and to allot and issue the shares of the Company pursuant to the exercise of the share options.

A circular containing, among other things, details of the Scheme will be despatched to the Shareholders in accordance with the requirements of the Listing Rules.

As at the date of this announcement, the Scheme remains subject to the approval of the Shareholders and the approval of the SASAC. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company’s securities.

By order of the Board
China Resources Pharmaceutical Group Limited
WANG Chuncheng
Executive Director

Hong Kong, 24 August 2017

As of the date of this announcement, the Board comprises Mr. FU Yuning as chairman and non-executive Director, Mr. WANG Chuncheng, Mr. SONG Qing and Mr. LI Guohui as executive Directors, Mr. CHEN Rong, Mr. YU Zhongliang, Mr. WANG Chenyang and Ms. WANG Jing as non-executive Directors, Mdm. SHING Mo Han Yvonne, Mr. KWOK Kin Fun, Mr. FU Tingmei and Mr. ZHANG Kejian as independent non-executive Directors.